methylmalonic acidemia

methylmalonic acidemia
Name	Methylmalonic acidemia
Synonyms	Methylmalonic aciduria
Field	Medical genetics, Metabolic disorder
Symptoms	Vomiting, lethargy, failure to thrive, developmental delay
Complications	Metabolic acidosis, Hyperammonemia, Pancreatitis, Renal failure
Onset	Infancy
Duration	Lifelong
Types	Isolated, combined with homocystinuria
Causes	Mutations in MMUT, MMAA, MMAB, MMADHC, MCEE genes
Risks	Autosomal recessive inheritance
Diagnosis	Newborn screening, GC-MS, Genetic testing
Differential	Propionic acidemia, Cobalamin deficiency
Prevention	Genetic counseling
Treatment	Dietary protein restriction, Carnitine supplementation, Antibiotics, Organ transplantation
Medication	Hydroxocobalamin
Prognosis	Variable; depends on subtype and metabolic stability
Frequency	~1 in 50,000 to 1 in 100,000 births

methylmalonic acidemia. It is an inherited metabolic disease characterized by the body's inability to properly process certain amino acids and fatty acids. This leads to a dangerous accumulation of Methylmalonic acid and other toxic compounds in the blood and tissues. The condition is caused by defects in the Methylmalonyl-CoA mutase enzyme or its associated cofactor, Adenosylcobalamin. Management typically requires a strict, lifelong medical and dietary regimen overseen by specialists in Biochemical genetics.

Signs and symptoms

Affected infants often present in the first days or weeks of life with severe Metabolic acidosis, Hyperammonemia, and Ketosis, leading to symptoms such as poor feeding, Vomiting, profound Lethargy, and Hypotonia. Without intervention, this can progress to Dehydration, Respiratory distress, Coma, and Death. In later-onset or milder forms, individuals may experience Failure to thrive, Developmental delay, movement disorders, and Intellectual disability. Chronic complications can include Growth retardation, Osteoporosis, Pancreatitis, and Chronic kidney disease, particularly Tubulointerstitial nephritis. Some patients are at risk for Basal ganglia damage, leading to a syndrome resembling Leigh syndrome.

Causes

The disorder is primarily caused by mutations in genes encoding enzymes or proteins involved in the metabolism of Methylmalonyl-CoA. The most common form results from deficient activity of Methylmalonyl-CoA mutase, encoded by the MMUT gene on Chromosome 6. Other forms involve defects in the synthesis or transport of its essential cofactor, Adenosylcobalamin, a form of Vitamin B12; these are linked to mutations in the MMAA, MMAB, MMADHC, and MCEE genes. All known genetic causes are inherited in an Autosomal recessive manner. The biochemical block leads to upstream accumulation of Propionyl-CoA, which is diverted into alternative, damaging metabolic pathways.

Diagnosis

Diagnosis is often initiated through expanded Newborn screening programs, which detect elevated levels of Propionylcarnitine (C3) on Tandem mass spectrometry. Confirmatory testing involves analyzing Urine for elevated Methylmalonic acid using techniques like GC-MS. Further biochemical characterization includes measuring Plasma total Homocysteine to distinguish isolated forms from Combined malonic and methylmalonic aciduria or disorders of Cobalamin metabolism. Definitive diagnosis is achieved through Genetic testing to identify pathogenic variants in the associated genes. Prenatal diagnosis is available for at-risk families through analysis of Amniotic fluid or Chorionic villus sampling.

Treatment

Acute metabolic crises require emergency management in a hospital, involving cessation of protein intake, administration of high-dose intravenous Glucose to suppress Catabolism, and correction of Acidosis with Sodium bicarbonate. Long-term management centers on a carefully calculated, protein-restricted diet using special medical formulas that are deficient in the precursor amino acids Isoleucine, Valine, Threonine, and Methionine. Supplementation with L-carnitine and Hydroxocobalamin (a form of Vitamin B12) is standard for responsive patients. Metronidazole or other Antibiotics may be used to reduce production of Propionate by gut Bacteria. For severe cases, Liver transplantation or combined Liver-kidney transplantation at centers like Boston Children's Hospital can be considered to stabilize metabolism.

Prognosis

The prognosis is highly variable and depends on the specific genetic subtype, the severity of enzyme deficiency, and the promptness and consistency of treatment. The neonatal-onset MUT deficiency form has historically had high mortality, but outcomes have improved with Newborn screening and aggressive management. Survivors often face significant neurodevelopmental challenges, Chronic kidney disease, and risk of metabolic stroke. Patients with defects in Cobalamin metabolism (e.g., CblA, CblB types) often have a better clinical response to Hydroxocobalamin therapy. Long-term follow-up by a multidisciplinary team at a specialized center like the National Institutes of Health is critical for managing complications and optimizing quality of life.

Epidemiology

Methylmalonic acidemia is considered a rare disorder, with an overall estimated incidence of approximately 1 in 50,000 to 1 in 100,000 live births. Incidence can vary significantly among different populations and ethnic groups due to founder mutations. For instance, a higher frequency has been reported in the Old Order Amish community of Pennsylvania and in the Saudi Arabian population. The widespread adoption of Tandem mass spectrometry in Newborn screening programs, such as those recommended by the American College of Medical Genetics, has increased the detection rate of the condition and allowed for earlier intervention.

Category:Inborn errors of metabolism Category:Autosomal recessive disorders